Drugs targeting the core pathologies of AD (anti-amyloid, anti-tau, and secretase inhibitors) and non-conventional interventions (e.g. probiotics and microbiome-based drugs, metabolism and bioenergetics, photo-oxygenation, SV2A modulators, active on mitochondrial stress, transfusion with young blood, among others)60,61 will need to show efficacy at reducing the risk for cognitive impairment and dementia. The gene discussed is MAPT; the disease is Alzheimer disease.